Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines.
Adjuvants, Immunologic
/ administration & dosage
Administration, Oral
Animals
Antibodies, Bacterial
/ immunology
Cholera
/ immunology
Cholera Vaccines
/ administration & dosage
Disease Models, Animal
Female
Galactosylceramides
/ administration & dosage
Immunity, Mucosal
/ drug effects
Immunization
Immunomodulation
/ drug effects
Male
Mice
T-Lymphocyte Subsets
/ immunology
Th1 Cells
/ immunology
Vibrio cholerae
/ immunology
Journal
Mucosal immunology
ISSN: 1935-3456
Titre abrégé: Mucosal Immunol
Pays: United States
ID NLM: 101299742
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
17
05
2018
accepted:
19
02
2019
revised:
26
01
2019
pubmed:
7
4
2019
medline:
11
4
2020
entrez:
7
4
2019
Statut:
ppublish
Résumé
Cholera is a severe diarrheal disease caused by the bacterium Vibrio cholerae (V. cholerae) that results in 3-4 million cases globally with 100,000-150,000 deaths reported annually. Mostly confined to developing nations, current strategies to control the spread of cholera include the provision of safe drinking water and improved sanitation and hygiene, ideally in conjunction with oral vaccination. However, difficulties associated with the costs and logistics of these strategies have hampered their widespread implementation. Specific challenges pertaining to oral cholera vaccines (OCVs) include a lack of safe and effective adjuvants to further enhance gut immune responses, the complex and costly multicomponent vaccine manufacturing, limitations of conventional liquid formulation and the lack of an integrated delivery platform. Herein we describe the use of the orally active adjuvant α-Galactosylceramide (α-GalCer) to strongly enhance intestinal bacterium- and toxin-specific IgA responses to the OCV, Dukoral
Identifiants
pubmed: 30953000
doi: 10.1038/s41385-019-0159-z
pii: S1933-0219(22)00282-3
pmc: PMC7746523
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Bacterial
0
Cholera Vaccines
0
Dukoral
0
Galactosylceramides
0
alpha-galactosylceramide
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1055-1064Références
Clemens J. D., Nair G. B., Ahmed T., Qadri F., Holmgren J. Cholera. Lancet. 390,1539–1549 (2017).
World Health Organisation. WHO report on global surveillance of epidemic-prone infectious diseases. 39–54 (2000). http://www.who.int/csr/resources/publications/surveillance/WHO_Report_Infectious_Diseases.pdf .
Anh, D. D. et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS. Negl. Trop. Dis. 5, e1006 (2011).
doi: 10.1371/journal.pntd.0001006
Shin, S., Desai, S. N., Sah, B. K. & Clemens, J. D. Oral vaccines against cholera. Clin. Infect. Dis. 52, 1343–1349 (2011).
doi: 10.1093/cid/cir141
Lebens, M. et al. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens. Vaccine 29, 7505–7513 (2011).
doi: 10.1016/j.vaccine.2011.06.121
Karlsson, S. L. et al. Development of stable Vibrio cholerae O1 Hikojima type vaccine strains co-expressing the Inaba and Ogawa lipopolysaccharide antigens. PLoS ONE 9, e108521 (2014).
doi: 10.1371/journal.pone.0108521
Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148–158 (2006).
doi: 10.1038/nri1777
Davitt, C. J. et al. A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens. J. Control Release 233, 162–173 (2016).
doi: 10.1016/j.jconrel.2016.05.001
Davitt, C. J. & Lavelle, E. C. Delivery strategies to enhance oral vaccination against enteric infections. Adv. Drug Deliv. Rev. 91, 52–69 (2015).
doi: 10.1016/j.addr.2015.03.007
Longet, S. et al. Thermostability of the coating, antigen and immunostimulator in an adjuvanted oral capsule vaccine formulation. Int. J. Pharm. 534, 60–70 (2017).
doi: 10.1016/j.ijpharm.2017.10.013
Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592–605 (2012).
doi: 10.1038/nri3251
Bhuiyan, T. R. et al. Cholera caused by Vibrio cholerae O1 induces T-cell responses in the circulation. Infect. Immun. 77, 1888–1893 (2009).
doi: 10.1128/IAI.01101-08
Weil, A. A. et al. Memory T-cell responses to Vibrio cholerae O1 infection. Infect. Immun. 77, 5090–5096 (2009).
doi: 10.1128/IAI.00793-09
Kuchta, A. et al. Vibrio cholerae O1 infection induces proinflammatory CD4+T-cell responses in blood and intestinal mucosa of infected humans. Clin. Vaccin. Immunol. 18, 1371–1377 (2011).
doi: 10.1128/CVI.05088-11
Hornquist, C. E., Ekman, L., Grdic, K. D., Schon, K. & Lycke, N. Y. Paradoxical IgA immunity in CD4-deficient mice. Lack of cholera toxin-specific protective immunity despite normal gut mucosal IgA differentiation. J. Immunol. 155, 2877–2887 (1995).
pubmed: 7673704
Kjerrulf, M. et al. Interferon-gamma receptor-deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance. Immunology 92, 60–68 (1997).
doi: 10.1046/j.1365-2567.1997.00312.x
Clemens, J., Shin, S., Sur, D., Nair, G. B. & Holmgren, J. New-generation vaccines against cholera. Nat. Rev. Gastroenterol. Hepatol. 8, 701–710 (2011).
doi: 10.1038/nrgastro.2011.174
World Health Organisation. WHO report on “Ending Cholera: A Global Roadmap to 2030”. http://www.who.int/mediacentre/news/releases/2017/partners-reduce-cholera/en/ . (2017)
Clemens, J. D. et al. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J. Infect. Dis. 158, 60–69 (1988).
doi: 10.1093/infdis/158.1.60
Arifuzzaman, M. et al. Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera. Clin. Vaccin. Immunol. 19, 1304–1311 (2012).
doi: 10.1128/CVI.00196-12
Leung, D. T. et al. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin. Vaccin. Immunol. 19, 690–698 (2012).
doi: 10.1128/CVI.05615-11
Harper, A. & Flanagan, K. L. Effect of sex on vaccination outcomes: important but frequently overlooked. Curr. Opin. Pharmacol. 41, 122–127 (2018).
doi: 10.1016/j.coph.2018.05.009
Sandberg, J. K., Bhardwaj, N. & Nixon, D. F. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur. J. Immunol. 33, 588–596 (2003).
doi: 10.1002/eji.200323707
Gourdy, P. et al. Relevance of sexual dimorphism to regulatory T cells: estradiol promotes IFN-gamma production by invariant natural killer T cells. Blood 105, 2415–2420 (2005).
doi: 10.1182/blood-2004-07-2819
Zeng, M., Nourishirazi, E., Guinet, E. & Nouri-Shirazi, M. The genetic background influences the cellular and humoral immune responses to vaccines. Clin. Exp. Immunol. 186, 190–204 (2016).
doi: 10.1111/cei.12841
Giaccone, G. et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8, 3702–3709 (2002).
pubmed: 12473579
Veldt, B. J. et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J. Hepatol. 47, 356–365 (2007).
doi: 10.1016/j.jhep.2007.04.018
Woltman, A. M. et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled phase I/II trial. Antivir. Ther. 14, 809–818 (2009).
doi: 10.3851/IMP1295
Nieda, M. et al. Therapeutic activation of Valpha24+Vbeta11+NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103, 383–389 (2004).
doi: 10.1182/blood-2003-04-1155
Chang, D. H. et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201, 1503–1517 (2005).
doi: 10.1084/jem.20042592
Uchida, T. et al. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57, 337–345 (2008).
doi: 10.1007/s00262-007-0373-5
Kunii, N. et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 100, 1092–1098 (2009).
doi: 10.1111/j.1349-7006.2009.01135.x
Nicol, A. J., Tazbirkova, A. & Nieda, M. Comparison of clinical and immunological effects of intravenous and intradermal administration of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells. Clin. Cancer Res. 17, 5140–5151 (2011).
doi: 10.1158/1078-0432.CCR-10-3105
Ano, G. et al. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae. Vaccine 29, 5758–5764 (2011).
doi: 10.1016/j.vaccine.2011.05.098
Lopez Y., et al. Repeated dose toxicity study of Vibrio cholerae-loaded gastro-resistant microparticles. J. Microencapsul. 31, 86–92 (2013).
Aguirre, T. A. et al. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv. Drug Deliv. Rev. 106(Pt B), 223–241 (2016).
doi: 10.1016/j.addr.2016.02.004
Svennerholm, A. M. et al. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J. Infect. Dis. 149, 884–893 (1984).
doi: 10.1093/infdis/149.6.884
Matias, W. R. et al. Antibody secreting cell responses following vaccination with bivalent oral cholera vaccine among haitian adults. PLoS. Negl. Trop. Dis. 10, e0004753 (2016).
doi: 10.1371/journal.pntd.0004753
Shamsuzzaman, S. et al. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. Vaccine 27, 1386–1392 (2009).
doi: 10.1016/j.vaccine.2008.12.041
Holmgren, J. et al. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 31, 2457–2464 (2013).
doi: 10.1016/j.vaccine.2013.03.027
Coulter I., McDonald B. F., Aversa V., Rosa M. Formulations. Google Patents. US7432294B2 (2014).